These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31688416)

  • 21. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.
    Palacios S; Nappi RE; Bruyniks N; Particco M; Panay N;
    Climacteric; 2018 Jun; 21(3):286-291. PubMed ID: 29553288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA study.
    Palma F; Xholli A; Cagnacci A;
    Maturitas; 2018 Feb; 108():18-23. PubMed ID: 29290210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.
    Palacios S; Cancelo MJ; Castelo Branco C; Llaneza P; Molero F; Borrego RS
    Climacteric; 2017 Feb; 20(1):55-61. PubMed ID: 28042734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of dyspareunia secondary to vulvovaginal atrophy.
    Fantasia HC
    Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.
    Levine KB; Williams RE; Hartmann KE
    Menopause; 2008; 15(4 Pt 1):661-6. PubMed ID: 18698279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depression, anxiety, and "the incredible shrinking vagina".
    Simon JA
    Menopause; 2020 Feb; 27(2):125-126. PubMed ID: 31977666
    [No Abstract]   [Full Text] [Related]  

  • 27. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study.
    Mercier J; Morin M; Lemieux MC; Reichetzer B; Khalifé S; Dumoulin C
    Menopause; 2016 Jul; 23(7):816-20. PubMed ID: 27219835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women.
    Panay N; Palacios S; Bruyniks N; Particco M; Nappi RE;
    Maturitas; 2019 Jun; 124():55-61. PubMed ID: 31097180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
    Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
    Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dyspareunia Related to GSM: Association of Total Vaginal Thickness via Transabdominal Ultrasound.
    Balica AC; Cooper AM; McKevitt MK; Schertz K; Wald-Spielman D; Egan S; Bachmann GA
    J Sex Med; 2019 Dec; 16(12):2038-2042. PubMed ID: 31542351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [How I do? a treatment with fractional CO
    Jardin I; Louis-Vahdat C; Canlorbe G; Mergui JL; Uzan C; Azaïs H
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):735-739. PubMed ID: 30266539
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment to External Labia and Vaginal Canal With CO2 Laser for Symptoms of Vulvovaginal Atrophy in Postmenopausal Women.
    Samuels JB; Garcia MA
    Aesthet Surg J; 2019 Jan; 39(1):83-93. PubMed ID: 29726916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Local estrogen therapy--clinical implications--2012 update].
    Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
    Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ospemifene in the treatment of vulvovaginal atrophy.
    Barnes KN; Pearce EF; Yancey AM; Forinash AB
    Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
    Edwards D; Panay N
    Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term reliability of fractioned CO
    Pieralli A; Bianchi C; Longinotti M; Corioni S; Auzzi N; Becorpi A; Fallani MG; Cariti G; Petraglia F
    Arch Gynecol Obstet; 2017 Nov; 296(5):973-978. PubMed ID: 28866727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
    Vicariotto F; Raichi M
    Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy.
    Salvatore S; Nappi RE; Parma M; Chionna R; Lagona F; Zerbinati N; Ferrero S; Origoni M; Candiani M; Leone Roberti Maggiore U
    Climacteric; 2015 Apr; 18(2):219-25. PubMed ID: 25333211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.